Abiopharma

🔍 Barchas Isaac (Executive)

Company: Immunome Inc. (IMNM)

Report Date: 2026-08-06

Detailed Transactions and Holdings:

• Sold 20,840 shares of Common Stock at $26.06 per share (Direct)
  Date: 2026-08-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 87,664.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 15,248 shares of Common Stock at $26.06 per share (Direct)
  Date: 2026-08-07 | Code: S | equity_swap_involved: 0 | shares_owned_after: 72,416.00 | transaction_form_type: 4 | Footnotes: F1, F4, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-06 | Code: H | shares_owned_after: 103,259.00

Footnotes:

• F1: The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026.
• F2: The weighted average sale price for the transaction report was $26.06, and the range of prices were between $26.00 and $26.3318, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
• F3: ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
• F4: The weighted average sale price for the transaction report was $26.06, and the range of prices were between $26.00 and $26.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.